PRODUCT DETAILS VIEW ALL PRODUCTS

Bactoclav injection (Amoxicillin + Potassium clavulanate)

  • Amoxycillin Trihydrate IP equivalanet to Amoxycillin 1000 mg and Potassium clavulanate IP equivalent to Clavulanic acid 200 mg injection
  • indicated for short-term treatment of bacterial infections at the followingsites:Upper respiratory tract infections (including ENT) e.g. recurrent tonsillitis, sinusitis,otitis media.Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar andbronchopneumonia.Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.Skin and soft tissue infections, e.g. boils, abscesses, cellulitis, wound infections.Bone and joint infections e.g. osteomyelitis.Other infections e.g. intra-abdominal sepsis. Bactoclav intravenous is also indicated for prophylaxis against infection which maybe associated with major surgical procedures such as gastrointestinal, pelvic, head andneck, cardiac, renal, joint replacement and biliary tract
  • Amoxicillin is a semisynthetic penicillin that inhibits enzymes in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin
  • Can be administered intravenously 6 to 8 hourly by intravenous injection (2 minutes) or intravenous infusion (30 minutes) until condition settles, followed by oral therapy with Bactoclav tablets at the recommended dose
  • Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients. History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam). is contra-indicated in patients with a previous history of drug associated jaundice/hepatic dysfunction
  • Not suitable for intramuscular or subcutaneousadministration.Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents. Convulsions may occur in patients with impaired renal function or in those receiving high doses. Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. Prolonged use may occasionally result in overgrowth of non-susceptible organisms
  • May be associated with an increased risk ofnecrotising enterocolitis in neonates. As with all medicines, use should be avoided inpregnancy, especially during the first trimester, unless considered essential by thephysician. May be administered during the period of lactation. With the exception ofthe risk of sensitisation, associated with the excretion of trace quantities in breast milk,there are no detrimental effects for the infant
  • Probenecid decreases the renal tubular secretion of amoxicillin. concomitant administration of allopurinol and ampicillin substantially increases the incidence of rashes in patients receiving both agents as compared to patients receiving ampicillin alone. Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity
  • The most commonly reported adverse drug reactions (ADRs) are diarrhoea,prolongation of bleeding time and prothrombin time
  • Anti-Bacterials